BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a sell rating to a hold rating in a report published on Friday, December 29th.
NTLA has been the subject of several other research reports. Credit Suisse Group increased their target price on shares of Intellia Therapeutics from $24.00 to $28.00 and gave the stock an outperform rating in a report on Friday, November 3rd. ValuEngine upgraded shares of Intellia Therapeutics from a sell rating to a hold rating in a report on Friday, September 22nd. Jefferies Group set a $42.00 target price on shares of Intellia Therapeutics and gave the stock a buy rating in a report on Tuesday, October 31st. Leerink Swann increased their target price on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an outperform rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. Finally, Wedbush reiterated an ourperform rating and issued a $25.00 price target (down previously from $29.00) on shares of Intellia Therapeutics in a research note on Wednesday, September 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $30.17.
Intellia Therapeutics (NTLA) opened at $21.45 on Friday. The firm has a market cap of $908.09 and a P/E ratio of -13.84. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $33.34.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $5.83 million. During the same quarter in the prior year, the company earned ($0.22) earnings per share. The business’s quarterly revenue was up 49.0% compared to the same quarter last year. equities research analysts expect that Intellia Therapeutics will post -1.68 earnings per share for the current fiscal year.
In other news, CEO Nessan Bermingham sold 336,783 shares of the stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $20.78, for a total value of $6,998,350.74. Following the transaction, the chief executive officer now directly owns 696,000 shares of the company’s stock, valued at $14,462,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,971,283 shares of company stock valued at $37,137,161. Corporate insiders own 12.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC bought a new position in Intellia Therapeutics during the second quarter worth about $101,000. Bank of Montreal Can increased its position in Intellia Therapeutics by 1,031.7% during the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after acquiring an additional 7,222 shares during the period. Nationwide Fund Advisors increased its position in Intellia Therapeutics by 117.7% during the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after acquiring an additional 4,351 shares during the period. State of Wisconsin Investment Board bought a new position in Intellia Therapeutics during the second quarter worth about $160,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Intellia Therapeutics during the second quarter worth about $167,000. 48.95% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/14/intellia-therapeutics-ntla-upgraded-to-hold-by-bidaskclub.html.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.